Bringing Innovation to Life
At Galderma, innovation isn’t just a buzzword; it is the cornerstone of our commitment to advancing dermatology. We stand out as one of the few forces capable of inventing, developing, and bringing to market truly innovative solutions for real-life patient needs.
Our Three Product Categories
We maintain sustainable growth by focusing on premium solutions trusted by healthcare professionals around the world:
- Injectable Aesthetics: Including neuromodulators and dermal fillers like Restylane® and Sculptra®.
- Dermatological Skincare: Featuring flagship brands like Cetaphil® and Alastin®.
- Therapeutic Dermatology: Addressing medical skin conditions with prescription solutions.
Skin Science: Bridging Art & Rigor
Our R&D pipeline features ambitious projects across all categories. As Dr. Flor A. Mayoral notes, the goal is to blend artistic sensibility with scientific rigor.
‘Galderma’s hyaluronic acid fillers offer infinite possibilities, allowing us to tailor treatments to each patient’s unique needs. This dedication to personalized care is what sets us apart.’
— Dr. Flor A. Mayoral, Dermatologist
Key Scientific Achievements
- NASHA® Technology: Proprietary technology used to improve the appearance of undereye hollows.
- PLLA-SCA™: A formulation that stimulates natural collagen production.
- Alastin Skincare: The fastest-growing brand in the physician-dispensed sub-segment.
Understanding Sensitive Skin
Recent studies reveal that modern, urban lifestyles significantly impact skin health. 70% of people globally now report having sensitive skin—a figure that has risen by 68% over the past two decades.
Beauty x Medicine
In our video series, Beauty x Medicine, our CEO Flemming Ørnskov explores the intersection of science and aesthetics. We are seeing a shift from ‘anti-aging’ to ‘pro-aging’—empowering people to look like the best version of themselves at every age.
The ‘Tweakments’ Revolution
Journalist Alice Hart-Davis coined the term ‘Tweakments’ to describe non-surgical procedures. These range from injectables to energy devices.
Emerging Trends
We have identified six trends shaping the future of aesthetics, including Fast Aesthetics and Expressionality.
Our Employees & Culture
Our employees are our greatest asset. We are committed to keeping our workplace respectful and inclusive.
Over 55% of our global workforce is made up of women, and we are proud to be certified as a Great Place to Work® in 15 affiliates.
Company at a Glance
Here is a snapshot of our global impact:
| Metric | Value | Year/Note |
|---|---|---|
| Net Sales | 4.41 Billion USD | 2024 |
| Employees | 7,000+ | Worldwide |
| Clinical Trials | 770+ | Funded since 2019 |
| Production | 330 Million Units | Per Year |
Technical Data Reference
Product: Nemluvio (nemolizumab) Approval: FDA / EMA Category: Biologic for Prurigo Nodularis Status: Active
*Source: Data retrieved from Galderma.com global reports.